We are seeking investors to finance the preclinical development of our ALS program and obtain approval for a first clinical trial in humans (planned for H2 2027).
Amount sought: approximately €5 million
Ongoing series: priming
Startup contact: boris.molle@invenis-biotherapies.com
Theme: Therapeutic Development
Applications: Brain diseases and disorders related to neurodegeneration
Partnerships and awards: I-lab Award 2022, ARSLA (ALS patient association), RHU 2023
Laboratory: Lille Neuroscience and Cognition (U1172)
Institutions: LILLE UNIVERSITY HOSPITAL / University of Lille / Taipei University
Intellectual property: 2 patents
Technology
Our acellular therapy is composed of platelet secretome, known to be a rich source of trophic factors that have the ability to modulate the various pathophysiological mechanisms (oxidative stress, neuroinflammation, cell survival, etc.) responsible for neurodegeneration.
Applications
Neurodegenerative diseases (NDs) such as Parkinson's disease (PD), Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and severe brain trauma (stroke, etc.)
Benefits
Our strategy offers the advantages of cell therapy (i.e., the delivery of trophic factors to the central nervous system) without its disadvantages (immune rejection, complex, non-standardized, and costly production processes, product variability).
Maturity
Therapeutic potential and safety validated in vivo for amyotrophic lateral sclerosis, Parkinson's disease, and traumatic brain injury. Development of GMP production of platelet lysate underway.
For more information
Contact your dedicated advisor